Commentary
Commentary
Lloyd Mack MD, FRCSC,
Corresponding Author
Lloyd Mack MD, FRCSC
Department of Surgical Oncology, University of Calgary/Tom Baker Cancer Centre, Calgary, Alberta, Canada
Dept. of Surgical Oncology, University of Calgary/Tom Baker Cancer Centre, 1331-29th St. N.W., Calgary, Alberta, Canada. Telephone: 403-944-1914; Fax: 403-283-1651Search for more papers by this authorLloyd Mack MD, FRCSC,
Corresponding Author
Lloyd Mack MD, FRCSC
Department of Surgical Oncology, University of Calgary/Tom Baker Cancer Centre, Calgary, Alberta, Canada
Dept. of Surgical Oncology, University of Calgary/Tom Baker Cancer Centre, 1331-29th St. N.W., Calgary, Alberta, Canada. Telephone: 403-944-1914; Fax: 403-283-1651Search for more papers by this authorFirst published: 18 July 2005
No abstract is available for this article.
REFERENCES
- 1 Jacks SP, Hundley JC, Shen P, et al.: Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. J Surg Oncol 2005; 91: 112–117.
- 2
Sadeghi B,
Arvieux C,
Glehen O, et al.:
Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study.
Cancer
2000;
88:
358–363.
10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O CAS PubMed Web of Science® Google Scholar
- 3 Witkamp AJ, de Bree E, Van Goethem AR, et al.: Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001; 27: 365–374.
- 4 Katz MH, Barone RM: The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin NA 2003; 12: 673–688.
- 5 Sticca RP, Dach BW: Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N A 2003; 12: 689–701.
- 6 Glehen O, Kwiatkowski F, Sugarbaker PH, et al.: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004; 22: 3284–3292.
- 7 Verwaal VJ, van Ruth S, de Bree E, et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737–3743.
- 8 Shen P, Levine EA, Hall J, et al.: Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003; 138: 26–33.
- 9 Sugarbaker PH: Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. EJSO 2001; 27: 239–243.
- 10 Elias D, Dube P, Bonvalot S, et al.: Treatment of liver metastases with moderate peritoneal carcinomatosis by hepatectomy and cytoreductive surgery followed by immediate post-operative intraperitoneal chemotherapy: Feasibility and preliminary results. Hepatogastroenterology 1999; 46: 360–363.
- 11 Elias D, Sideris L, Liberale G, et al.: Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery 2005; 137: 411–416.
- 12 Verwaal VJ, Van Tinteren H, Ruth SV, et al.: Toxicity of cytoreduction surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85: 61–67.
- 13 McQuellon RP, Loggie BW, Fleming RA, et al.: Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. EJSO 2001; 27: 65–73.
